Condition: Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Waldenstrom Macroglobulinemia (WM) · Sponsor: Nurix Therapeutics, Inc.
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
This description comes directly from the study's public registry record.
Patient Outreach · (415)-230-7806 · nx2127001@nurixtx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of California Irvine | Orange, California, United States | Completed |
| University of California San Francisco Medical Center | San Francisco, California, United States | Completed |
| Sarah Cannon Research Institute at Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Mount Sinai Comprehensive Cancer Center | Miami Beach, Florida, United States | Completed |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Sarasota, Florida, United States | Completed |
| The University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| National Institutes of Health Clinical Center | Bethesda, Maryland, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Completed |
| University of Cincinnati Medical Center | Cincinnati, Ohio, United States | Completed |
| OSU Wexner Medical Center | Columbus, Ohio, United States | Completed |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04830137